Brief: CG Oncology Announces 74.5% Complete Response In Phase 3 Trial

CG Oncology

05/12/2024 12:06

Dec 5 (Reuters) - CG Oncology Inc  CGON.O :
    * GROUNDBREAKING CRETOSTIMOGENE GRENADENOREPVEC MONOTHERAPY
DATA
DEMONSTRATES SUSTAINED, DURABLE COMPLETE RESPONSES IN HIGH-RISK
BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER
    * CG ONCOLOGY INC - ANNOUNCES 74.5% COMPLETE RESPONSE IN
PHASE 3
TRIAL
    * CG ONCOLOGY INC - NO GRADE 3 OR GREATER TREATMENT-RELATED
ADVERSE EVENTS REPORTED

Source text:  ID:nGNX4DmLln 
Further company coverage:  CGON.O 

 ((Reuters.Briefs@thomsonreuters.com;))